FDA product code · Clinical chemistry

Radioimmunoassay, Glucagon

Name: FDA decisions, review times, recalls and adverse event reports for product code JME
Creator: 510(k) Report

JMEClass I21 CFR 862.1335510(k) exempt3 decisions since 19780 recalls

FDA lists JME as exempt from 510(k): a device of this type needs no clearance unless one of the limits in 21 CFR 862.9 applies, such as a new intended use or a different fundamental technology. 3 FDA decisions since 1978. No recall names this code.

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026 Download the data (CSV)

FIG. A — Illustration, clinical chemistry panel

Twenty years of JME at a glance: how often FDA decides these devices, how long 510(k) reviews take, how often they are recalled, and how many adverse event reports name the code.

FDA decisions per year · JME

FDA has decided no JME device since 2007.

Median 510(k) review, days · JME

Too few JME 510(k)s in any year since 2007 to give a median.

Recalls per year · JME

No recall names JME since 2007.

Adverse event reports per year · JME

No MAUDE report names JME since 2007.

View these four charts as a table

Year	Median 510(k) review, days	MAUDE reports
2007	—	0
2008	—	0
2009	—	0
2010	—	0
2011	—	0
2012	—	0
2013	—	0
2014	—	0
2015	—	0
2016	—	0
2017	—	0
2018	—	0
2019	—	0
2020	—	0
2021	—	0
2022	—	0
2023	—	0
2024	—	0
2025	—	0
2026	—	—

FIG. 1 — JME by year, 2007–2026Sources: FDA decision databases, recall and enforcement reports, MAUDE · Data through Oct 25, 2026

Planning a device in JME? A 510(k) Report ranks candidate predicates in this code by lineage, citations and recall history, with the review-time outlook.

See the 510(k) Report

Radioimmunoassay, Glucagon

What has FDA decided in JME lately?